ANI PHARMACEUTICALS INC (ANIP) insider trading

By person

16 insiders · 50 transactions

29.0×

Nikhil Lalwani holds 29.0 times base salary in stock. $24.32M of shares against $837.41K in salary for 2025.

Salary from the company's own proxy. The shares are what Nikhil Lalwani last reported holding, valued at $72.87, the price Common Stock was last bought or sold at on the open market here, on 29 Oct 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Nikhil Lalwani

President & CEO

—

$5.44M (4)

−$5.44M

333,689

1.48%

$24.32M

−10.7%

Patrick D Walsh

Director

—

$2.32M (4)

−$2.32M

38,432

0.1709%

$2.80M

−48.6%

Stephen P. Carey

SVP & CFO

—

$2.20M (9) scheduled

−$2.20M

166,143

0.7387%

$12.11M

+2.6%

Christopher Mutz

Head of Rare Disease

—

$1.64M (6) scheduled

−$1.64M

91,309

0.4060%

$6.65M

+9.6%

Chad Gassert

SVP - Corp. Dev. & Strategy

—

$1.31M (2)

−$1.31M

233,406

1.04%

$17.01M

−3.9%

Krista Davis

SVP, Chief HR Officer

—

$918.62K (5) scheduled

−$918.62K

51,946

0.2310%

$3.79M

+3.8%

Ori Gutwerg

SVP, Generics

—

$621.44K (3)

−$621.44K

75,534

0.3358%

$5.50M

−2.2%

Meredith Cook

Sr. VP, General Counsel & Sec.

—

$454.63K (12) scheduled

−$454.63K

73,424

0.3265%

$5.35M

+30.0%

Thomas Andrew Rowland

SVP, Head - Established Brands

—

$393.83K (2)

−$393.83K

38,271

0.1702%

$2.79M

+9.6%

Thomas Haughey

Director

—

$161.76K (1) scheduled

−$161.76K

38,878

0.1729%

$2.83M

−24.5%

Renee P Tannenbaum

Director

—

$146.07K (1)

−$146.07K

29,514

0.1312%

$2.15M

+30.5%

Jeanne Thoma

Director

—

$71.53K (1) scheduled

−$71.53K

26,762

0.1190%

$1.95M

−34.1%

Muthusamy Shanmugam

Head of R&D, COO-Novitium Ops

—

532,976

2.37%

$38.84M

−24.0%

Antonio R Pera

Director

—

27,017

0.1201%

$1.97M

−13.0%

Matthew J Leonard

Director

—

11,221

0.0499%

$817.67K

−6.4%

Henry O Gosebruch

Director

—

6,662

0.0296%

$485.46K

—

ANI PHARMACEUTICALS INC

What the insiders did Net selling

By person